Clinical trials
Psychosis clinical trials
Below are recruiting psychosis clinical trials, each written for real people, not researchers. We’re tracking 146 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06774430Recruiting
Digital outreach for young people at risk of psychosis
This study tests a digital program designed to encourage young people to seek help for early signs of psychosis. It aims to see if online messages can increase connections to care.
New York, New YorkAges 12–29 - NCT06774417Recruiting
Digital strategies to help young people seek help for mental health
This trial tests a digital tool designed to help young people recognize early signs of mental health conditions and take steps toward getting help. It may be a good fit if you are between 12 and 29, live near certain research sites, and can complete a short screening questionnaire in English.
New York, New YorkAges 12–29 - NCT06608706Recruiting
Integrated trauma treatment for psychosis
This trial tests a new way to treat trauma in people who have psychosis (like schizophrenia). It combines therapy for trauma with your usual care, and aims to help you feel less distressed by past traumatic events.
BergenAges 16 years+ - NCT06224530Recruiting
Testing levetiracetam's effect on brain function in psychosis risk
This trial tests whether a single dose of levetiracetam, a medication that affects brain chemistry, can change brain function and thinking in people at risk for psychosis. The goal is to see if it might help prevent symptoms from worsening.
London, LondonAges 18–40 - NCT06194799Enrolling by invitationPhase 3
Long-term ACP-204 for Alzheimer's psychosis
This study tests a long-term medicine (ACP-204) for people with Alzheimer's disease who also have psychosis (hallucinations or delusions). If you took part in the earlier ACP-204 study, this open-label extension lets you continue receiving the medicine to see how well it works over time.
Costa Mesa, CaliforniaAges 55–95 - NCT06159673RecruitingPhase 2/Phase 3
ACP-204 for Alzheimer's with psychosis
This study tests a new medicine called ACP-204 for people with Alzheimer's disease who also have psychosis (like seeing or hearing things that aren't real). It aims to see if the drug can help reduce these symptoms safely.
Chandler, ArizonaAges 55–95 - NCT06107764Recruiting
Brain stimulation study for thinking and memory in psychosis
This trial tests whether a non-invasive brain stimulation technique (rTMS) can improve thinking and memory in people with psychosis. It involves MRI scans and several study visits at McLean Hospital.
Belmont, MassachusettsAges 18–55 - NCT06118268Recruiting
Brain stimulation to improve social thinking in psychosis
This study tests whether a type of brain stimulation called intermittent theta burst stimulation (iTBS) can help improve social thinking and understanding in people with psychosis. Researchers want to see if this treatment can boost how you read social cues and connect with others.
Glen Oaks, New YorkAges 18–39 - NCT06036316Recruiting
Language and memory study for people with psychosis
This study looks at how language and memory interact in people with psychosis, including those at risk, early psychosis, or schizophrenia, as well as healthy volunteers. It aims to understand these connections better, which may help improve care.
Laxou, FranceAges 16–55 - NCT05968560Recruiting
Online therapy to help youth at risk for psychosis
This trial tests a telehealth (video/phone) version of cognitive behavioral therapy to help young people who are at risk for developing psychosis. It may help by teaching skills to reduce symptoms and improve coping, with support from a key family or close person.
New York, New YorkAges 14–25 - NCT05131035Recruiting
Trial for thinking-speed training to lower psychosis risk
This study targets problems with “processing speed,” or how fast your brain handles information, to see if it can improve social functioning and lower the risk of developing full psychosis. It’s for people who are considered at high risk for psychosis but do not already have schizophrenia.
Glen Oaks, New YorkAges 14–20 - NCT05813457Recruiting
Early identification program for first episode psychosis
This study checks whether finding and starting care early for a first episode of psychosis can shorten how long symptoms go untreated. You may be eligible if it’s your first episode and you haven’t been on antipsychotic medicines for long before now.
BronAges 15–35 - NCT05796401RecruitingPhase 3
Personalized care program for early psychosis outcomes
This trial tests whether a personalized care plan improves day-to-day functioning for people in the early stages of psychosis. It aims to see if adding structured support after a recent diagnosis can help you function better.
BrestAges 15–30 - NCT05619822Enrolling by invitation
Third-steps therapy for psychosis and PTSD symptoms
This study tests a structured therapy program for people who have both psychosis symptoms and high PTSD symptoms. It aims to reduce distress from past trauma while also supporting mental health symptoms.
Pozuelo de Alarcón, MadridAges 18–65 - NCT05511363RecruitingPhase 3
Study of a new medicine for psychosis in Alzheimer's disease
This trial tests a new drug called KarXT to see if it can safely reduce hallucinations and delusions in people with Alzheimer's disease. If you or a loved one has Alzheimer's and experiences these symptoms, this study might offer a new treatment option.
Homewood, AlabamaAges 55–90 - NCT05445180Recruiting
Brain scan study of thinking in cannabis users with psychosis
This study uses brain imaging to understand how thinking works in people who use cannabis, comparing those with psychosis to people without psychosis. It may help researchers learn what brain patterns relate to thinking difficulties and how cannabis use fits in.
Montreal, QuebecAges 16–80 - NCT05440214Recruiting
Therapy to reduce suicide risk in people with psychosis
This trial tests an approach aimed at emotional ups-and-downs to help lower suicide risk in people who have psychosis and are at higher risk for suicidal thoughts or behaviors. If you qualify, you would get outpatient mental health care while participating in the study.
Baltimore, MarylandAges 18 years+ - NCT04411225RecruitingPhase 3
CBD may help early psychosis along with usual treatment
This Phase 3 trial tests whether taking cannabidiol (CBD) can reduce symptoms when added to standard care for early psychosis (like first-episode psychosis or attenuated psychosis). It may help some people have fewer troubling thoughts or perceptions over time.
La Jolla, CaliforniaAges 16–30 - NCT04373317RecruitingPhase 4
Comparing two medicines for hallucinations in Parkinson's disease
This study compares two drugs, pimavanserin and quetiapine, to see which works better for hallucinations or delusions caused by Parkinson's disease. The goal is to help patients manage these symptoms more effectively.
Tucson, ArizonaAges 40 years+ - NCT04323566Enrolling by invitationPhase 2
Rituximab for OCD or psychosis linked to immune inflammation
This trial tests rituximab (an immune system medicine) to see if it can reduce OCD symptoms and/or psychosis when there are signs the immune system may be involved. You may be considered if other standard psychiatric treatments have not helped enough and your illness seems relatively recent with possible inflammation clues.
UppsalaAges 18–55 - NCT04007510Enrolling by invitation
Early psychosis study for patients, families, and care teams
This study looks at how to improve early psychosis care using data-driven planning and support for people who are newly developing symptoms. It may help by sharing better ways to coordinate treatment among patients, families, and the clinic/community teams.
Sacramento, CaliforniaAges 8–40 - NCT05074732Recruiting
Study of forensic mental health admissions after a service move
This study looks at all adult admissions to Ireland’s National Forensic Mental Health Service during a specific time window. It may help improve how the new forensic service at Portrane runs in the future.
DublinAges 18 years+ - NCT06048172Recruiting
Trauma therapy for PTSD with a psychotic disorder
This trial tests if prolonged exposure therapy, a common PTSD treatment, can help people who also have a psychotic disorder (like schizophrenia or bipolar with psychosis). The goal is to reduce PTSD symptoms.
HamburgAges 18 years+ - NCT06197048Recruiting
Nutrition counseling for schizophrenia or bipolar disorder
This study tests whether nutritional counseling can improve body measurements and health markers in people with schizophrenia, psychosis, or bipolar disorder. It may help you manage weight and overall health.
Drammen, AkershusAges 18 years+
Hear when a new Psychosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for psychosis?
- Yes. Clin2 currently lists 146 recruiting psychosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a psychosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a psychosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.